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OBJECTIVE—Recent studies identiﬁed accumulation of reac-
tive oxygen species (ROS) as a common pathway causing insulin
resistance. However, whether and how the reduction of ROS
levels improves insulin resistance remains to be elucidated. The
present study was designed to deﬁne this mechanism.
RESEARCH DESIGN AND METHODS—We investigated the
effect of overexpression of superoxide dismutase (SOD)1 in
liver of obese diabetic model (db/db) mice by adenoviral
injection.
RESULTS—db/db mice had high ROS levels in liver. Overexpres-
sion of SOD1 in liver of db/db mice reduced hepatic ROS and
blood glucose level. These changes were accompanied by im-
provement in insulin resistance and reduction of hepatic gene
expression of phosphoenol-pyruvate carboxykinase and peroxi-
some proliferator–activated receptor  coactivator-1 (PGC-1),
which is the main regulator of gluconeogenic genes. The inhibi-
tion of hepatic insulin resistance was accompanied by attenua-
tion of phosphorylation of cAMP-responsive element-binding
protein (CREB), which is a main regulator of PGC-1 expression,
and attenuation of Jun NH2-terminal kinase (JNK) phosphoryla-
tion. Simultaneously, overexpression of SOD1 in db/db mice en-
hanced the inactivation of forkhead box class O1, another regulator
of PGC-1 expression, without the changes of insulin-induced Akt
phosphorylation in liver. In hepatocyte cell lines, ROS induced
phosphorylation of JNK and CREB, and the latter, together with
PGC-1 expression, was inhibited by a JNK inhibitor.
CONCLUSIONS—Our results indicate that the reduction of
ROS is a potential therapeutic target of liver insulin resistance, at
least partly by the reduced expression of PGC-1. Diabetes 57:
2083–2091, 2008
A
ccumulation of reactive oxygen species (ROS)
plays a critical role in the pathogenesis of
various diseases. ROS are generated by the
electron transport chain in mitochondrial res-
piration and are thus increased in conditions associated
with enhanced oxidation of energy substrate such as
glucose and free fatty acids. Furthermore, ROS is pro-
duced by NADPH oxidase, which is activated by various
cytokines. The state of insulin resistance is accompanied
by increases in the levels of blood glucose, free fatty acids,
and adipocytokines and is thus regarded as a state of
increased exposure to ROS (1,2). Although the exact mech-
anism of insulin resistance is not fully understood, recent
data implicate ROS in the pathogenesis of multiple forms of
insulin resistance (3–5). However, there is little or no infor-
mation on how ROS induce insulin resistance in vivo.
The tissue ROS level in each organ depends on the
production and elimination of ROS. Superoxide dismuta-
ses (SODs) are major antioxidant enzymes that degrade
superoxide into hydrogen peroxide. At present, three
distinct isoforms of SOD have been identiﬁed in mammals
(6). SOD1, or CuZn-SOD, is a copper- and zinc-containing
homodimer. Although this enzyme had been regarded to
be expressed exclusively in the cytoplasm, at least in
rodent liver, it is found both in the intermembrane space of
mitochondria and in the cytosol (7). SOD2, or Mn-SOD, is
a manganese-containing enzyme found almost exclusively
in the mitochondria. SOD3, or EC-SOD, is the most re-
cently characterized SOD; it exists as a copper- and
zinc-containing tetramer and contains a signal peptide that
directs this enzyme exclusively to extracellular spaces.
The present study was designed to explore the effect of
ROS on hepatic insulin resistance. For this purpose, we
injected an adenovirus encoding human SOD1 (AdSOD1)
into db/db mice, a genetic model of type 2 diabetes. The
results demonstrated that reduction of ROS in liver
improved glucose tolerance with reduced expression of
gluconeogenic genes. The reduced expression of perox-
isome proliferator–activated receptor  coactivator-1
(PGC-1), independent of insulin signaling at the Akt
phosphorylation level, seems to be involved in this
mechanism.
RESEARCH DESIGN AND METHODS
Recombinant adenoviral vectors. The recombinant adenovirus AdSOD1
encoding human SOD1 was kindly provided by Dr. David A. Brenner (Univer-
sity of North Carolina) (8). The control adenovirus encoding -galactosidase
(AdLacZ) was kindly provided by Dr. Michael S. German (University of
California San Francisco). Both adenoviruses were ampliﬁed in human
embryonic kidney (HEK)-293 cells and puriﬁed by cesium chloride density
centrifugation. Viral titers were determined by the method of tissue culture
infective doses 50.
Animals and administration of recombinant adenovirus. The study was
reviewed and approved by the animal care and use committee of Juntendo
University. Speciﬁc-pathogen–free female C57BL/KsJ-db/db mice and their
lean littermates, C57BL/KsJ-db/m mice, were purchased from Japan Clea
(Tokyo, Japan). All mice were housed in stainless steel wire cages in a
temperature-controlled clean room with a 12:12 h light-dark cycle. The
animals were provided with standard diet and autoclaved tap water ad libitum.
AdSOD1 or AdLacZ (5  10
7 plaque-forming units) diluted in PBS buffer or the
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DIABETES, VOL. 57, AUGUST 2008 2083same volume of PBS alone was injected through the tail vein of 12- to
18-week-old db/db mice, whose fasting blood glucose values had reached
180 mg/dl. Blood samples were collected from the tail vein to measure blood
glucose and insulin concentrations. Mice were sacriﬁced under anesthesia
induced by intraperitoneal injection of sodium pentobarbital (50 mg/kg)
(Nembutal; Abbott Laboratories, Abbott Park, IL).
Visualization of intracellular superoxide. The oxidation-dependent ﬂuo-
rescent dye dihydroethidium (DHE) (Sigma Chemical, St. Louis, MO) was
used to evaluate in situ production of superoxide (9). Unﬁxed frozen livers
were cut into 5-m-thick sections, which were placed on glass slides. Twenty
micromolars of DHE were applied to the surface of each tissue section, and
the slides were incubated in a light-protected humid chamber at 37°C for 30
min. Images were obtained with a microscope (DXM1200; Nikon, Tokyo,
Japan) equipped with a krypton/argon laser. Laser and power settings were
identical during acquisition of images of various specimens. Fluorescence was
detected with a 585-nm-long pass ﬁlter.
Laboratory tests. Blood glucose concentrations were measured by a porta-
ble glucose meter using the One Touch Ultra (LifeScan, Milpitas, CA). Plasma
insulin was measured using an insulin ELISA kit (Morinaga, Takamatsu,
Japan).
Nitrotyrosine assay. Nitrotyrosine was measured with a nitrotyrosine ELISA
kit (OxisResearch, Foster City, CA) (10) using whole-cell extracts of each
liver.
Intraperitoneal glucose tolerance, insulin tolerance, and pyruvate
challenge tests. At 5 days after adenovirus infection, mice were injected
intraperitoneally with glucose (0.5 g/kg body wt), regular insulin (2 units/kg
body wt) (Humulin; Eli Lilly, Indianapolis, IN), or pyruvate (1.5 g/kg body wt),
as previously described (11); blood glucose and serum insulin levels were
subsequently measured as described above.
Immunoprecipitation assay and Western blot analysis. To determine the
tissue distribution of SOD1 expression, various tissues were isolated at 7 days
after infection with the adenovirus. To investigate the effect of adenovirus
injection, after overnight fasting, the livers were isolated, weighed, and
snap-frozen in liquid nitrogen. Some livers were collected at 5 min after
injection of 0.5 units regular insulin through inferior vena cava. The isolated
tissues were then homogenized by a handheld homogenizer in radioimmuno-
protein assay buffer (12). The samples were sonicated on ice and centrifuged
at 15,000g at 4°C for 30 min. The supernatants were collected and Western
blotting analysis was performed as previously described (13). For the immu-
noprecipitation assay, the isolated tissues were homogenized in radioimmu-
noprotein assay buffer and immunoprecipitation was conducted by incubating
supernatant containing the same amount of protein with the indicated
antibody and protein G sepharose for 1 hour at 4°C (12). Anti–CuZn-SOD
antibody, anti–PGC-1 antibody, and anti-forkhead transcription factor
(FKHR) (H-128) antibody were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Anti–insulin receptor substrate (IRS)-1 antibody, anti–
phospho-IRS-1(Ser
307) antibody, anti–IRS-2 antibody, anti-phosphotyrosine,
clone 4G10 antibody, anti–phosphatidylinositol 3 (PI3)-kinase p85 antibody,
and anti-Akt1/protein kinase B- antibody were obtained from Upstate
Biotechnology (Lake Placid, NY). Anti-phosphoAkt (Ser
473) antibody, anti–
cAMP-responsive element-binding protein (CREB) antibody, anti-phospho-
CREB (Ser
133) antibody, anti-p44/p42 (extracellular signal–related kinase
[ERK]) antibody, anti–phospho-ERK (Thr
202/Tyr
204) antibody, anti–phospho-
FKHR (Ser
256) antibody, anti-p38 antibody, anti–phospho-p38 (Thr
180/Tyr
182)
antibody, anti–stress-activated protein kinase (SAPK)/JNK antibody, and
anti–phospho-SAPK/JNK (Thr
183/Tyr
185) antibody were obtained from Cell
Signaling Technology (Beverly, MA). Horseradish peroxidase–conjugated
anti-rabbit and anti-mouse antibodies were purchased from Bio-Rad Labora-
tories (Tokyo, Japan).
Isolation of tissue RNA and real-time quantitative RT-PCR. Total RNA
was extracted from livers by using TRIzol reagent (Invitrogen, Carlsbad, CA).
cDNAs were then synthesized using Superscript III RNase H Reverse Tran-
scriptase (Invitrogen) and oligo-dT primers. The resulting cDNAs were
ampliﬁed using SYBR Green PCR kit (Applied Biosystems, Foster City, CA).
Quantitative PCR was performed on an ABI PRISM 7700 sequence detection
system (Perkin Elmer Life Sciences, Boston, MA). The relative abundance of
mRNAs was calculated by the comparative cycle of threshold (CT) method
with TATA box–binding protein mRNA as the invariant control. The primer
sequences for mouse PGC-1, phosphoenol-pyruvate carboxykinase
(PEPCK), glucose-6-phosphatase (G6Pase), and glucokinase were previously
shown (11). The following primers were also used: TATA box–binding protein
(mouse) forward CTCAGTTACAGGTGGCAGCA and reverse ACCAACAATC
ACCAACAGCA, IRS-2 (mouse) forward CAGCTATTGGGACCACCACT and
reverse GTAGTTCAGGTCGCCTCTGC, PGC-1 (human) forward CCTGCAT
GAGTGTGTGCTCT and reverse GCAAAGAGGCTGGTCTTCAC, and TATA
box–binding protein (human) forward CGGCTGTTTAACTTCGCTTC and
reverse TTCTTGGCAAACCAGAAACC.
Cell culture. Human Huh7 hepatocarcinoma cells were kindly provided by
Dr. Kenichi Ikejima (Juntendo University, Tokyo). We cultured Huh7 cells in
high-glucose Dulbecco’s modiﬁed Eagle’s medium supplemented with 10%
A
AdSOD1
MW:15.9
(kDa)
MW:19.0
Organ:
db/m db/db
db/db   AdLacZ db/db   AdSOD1
B
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
db/m db/db AdLacZ AdSOD1
R
e
l
a
t
i
v
e
 
n
i
t
r
o
t
y
r
o
s
i
n
e
 
l
e
v
e
l
C
* *
FIG. 1. Expression of SOD1 and quantiﬁcation of ROS after injection of
AdSOD1 in db/db mice. A: Seven days after intravenous injection of
AdSOD1 (5  10
7 plaque-forming units each) into db/db mice, each
organ was harvested and 20 g of tissue extracts were immunoblotted
with tissue extracts from the liver of AdLacZ-infected db/db mice and
PBS-injected db/db and db/m mice using anti-SOD1 antibody. The
19.0-kDa band represents human SOD1 coded in AdSOD1, and the
15.9-kDa band represents endogenous mouse SOD1. B: Seven days
after the injection of PBS into db/m mice or db/db mice or injection of
AdLacZ or AdSOD1 into db/db mice, the amount of ROS in the liver was
visualized by DHE staining. C: Quantitative analysis of nitrotyrosine in
the liver at 7 days after adenovirus or PBS injection by ELISA. The
acquired data by ELISA were corrected for the protein concentration
in each sample (db/m, n  4; db/db, n  6; AdLacZ-treated db/db, n 
10; and AdSOD1-treated db/db, n  10). The relative expression level
was expressed by setting the expression level in the db/m as 1. Values
are expressed as means  SD. *P < 0.05 vs. db/db and AdLacZ groups.
(Please see http://dx.doi.org/10.2337/db08-0144 for a high-quality digi-
tal representation of this ﬁgure.)
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2084 DIABETES, VOL. 57, AUGUST 2008FCS, 100 units/ml penicillin, and 100 g/ml streptomycin at 37°C in a
humidiﬁed 5% CO2 environment. To load ROS, Huh7 cells were grown to
conﬂuence on six-well plates, incubated overnight in serum-free low-glucose
Dulbecco’s modiﬁed Eagle’s medium, and then treated with 400 mol/l
xanthine and 40 mU/ml xanthine oxidase (Sigma) for the indicated time. For
analysis of the antioxidant effect, cells were treated with 400 mol/l butylated
hydroxyanisole (BHA) (Sigma) (14,15) or 400 mol/l manganese (III) tetrakis
(4-benzoicacid) porphyrin (MnTBAP) (A.G. Scientiﬁc, San Diego, CA) (3) 20
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FIG. 2. Effect of overexpression of AdSOD1 in liver on various metabolic parameters. Serial changes in nonfasting blood glucose level (A) and
body weight (B) after injection of AdSOD1, AdLacZ, or PBS into db/db mice (n  3 for each group). Blood glucose (C) and immunoreactive insulin
concentrations (D) after intraperitoneal injection of glucose (0.5 g/kg) at 5 days after each treatment (AdLacZ group, n  7; AdSOD1 group, n 
6). E: Blood glucose changes (% change) after intraperitoneal injection of 2 units/kg body wt of regular insulin (Humulin) at 5 days after each
treatment. Values were calculated by setting the starting blood glucose concentration in each group as 100% (n  5 for each group). F: Five days
after each treatment, blood glucose concentrations were measured following intraperitoneal pyruvate injection (1.5 g/kg) after overnight fasting
(n  5 for each group) as an index of the extent of gluconeogenesis. Values are expressed as means  SD. *P < 0.05 vs. AdLacZ and PBS groups.
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DIABETES, VOL. 57, AUGUST 2008 2085min before the addition of xanthine and xanthine oxidase load. After
treatment for the indicated time, cells were washed with PBS and harvested
with a scraper. Protein samples or RNA samples were prepared from the
lysates and applied for Western blotting or real-time PCR, respectively. In
some experiments, we used SP600125 (Calbiochem, San Diego, CA), which is
a speciﬁc inhibitor of JNK.
Statistical analysis. Results are expressed as means  SD. Differences
between two groups were analyzed for statistical signiﬁcance by Student’s t
test for unpaired comparisons. Comparisons among more than two groups
were assessed with ANOVA, followed by a Bonferroni test. A P value 0.05
was considered statistically signiﬁcant.
RESULTS
AdSOD1 treatment reduces hepatic ROS in db/db
mice. To investigate the effect of reduction of ROS in liver
on insulin resistance, we overexpressed SOD1 protein in
liver of db/db mice by tail-vein injection of AdSOD1,
followed by determination of SOD1 gene expression in
various organs. Although the expression level of endoge-
nous SOD1 (estimated molecular weight 15.9 kDa) in the
liver of db/db mice was not less than that in db/m mice,
endogenous SOD1 was expressed in every organ investi-
gated. On the other hand, exogenous human SOD1 (esti-
mated molecular weight 19.0 kDa) was detected only in
AdSOD1-treated liver (Fig. 1A). To investigate the effect of
SOD1 expression on ROS level in the liver, we stained
each liver with the oxidation-dependent ﬂuorescent dye
DHE. Hepatic overexpression of SOD1 was associated
with reduced level of superoxide in liver to a level com-
parable with that in db/m mice (Fig. 1B). This effect was
persistently observed from 1 to at least 7 days after the
injection of AdSOD1 (data not shown). Nitrotyrosine, a
representative marker of protein oxidation in liver of db/db
mice, was higher than in db/m mice. Injection of AdSOD1
into db/db mice signiﬁcantly reduced nitrotyrosine level to
a level comparable with that in db/m mice, whereas
injection of AdLacZ into db/db mice did not alter nitro-
tyrosine level (Fig. 1C). These results show that AdSOD1
treatment reduced the increased ROS in the liver of db/db
mice to a level compatible with that of db/m mice.
Hepatic expression of SOD1 ameliorates glucose in-
tolerance in db/db mice. To elucidate the effect of the
reduction of hepatic ROS on glucose metabolism, we
investigated the effect of SOD1 overexpression in liver on
blood glucose level in db/db mice. As shown in Fig. 2A,
treatment with AdSOD1 induced marked reduction of
nonfasting blood glucose level from 2 days after AdSOD1
injection, and this effect continued for at least 33 days.
Body weight of AdSOD1-treated mice was higher than that
of AdLacZ- mice and PBS-injected control mice (Fig. 2B).
We measured food intake in each group. Food intake of
AdSOD1-treated mice was comparable with that of Ad-
LacZ-treated and PBS-treated mice (data not shown).
Accordingly, the increase in body weight in AdSOD1-
treated mice was independent of food intake. Intraperito-
neal glucose tolerance test revealed that AdSOD1
treatment ameliorated glucose tolerance without an in-
crease in serum insulin level during glucose load (Fig. 2C
and D). Intraperitoneal insulin tolerance test revealed that
AdSOD1-treated mice had better insulin sensitivity than
AdLacZ-treated mice (Fig. 2E). To conﬁrm that the im-
provement of insulin resistance was mainly due to changes
in hepatic glucose metabolism, we measured blood glu-
cose levels after intraperitoneal injection of pyruvate,
which is the main precursor of gluconeogenesis. The
increase in blood glucose level after pyruvate injection
was signiﬁcantly lower in AdSOD1-treated mice than in
AdLacZ-treated mice (Fig. 2F). These data indicate that
hepatic overexpression of SOD1 improved glucose toler-
ance mainly by improvement of insulin sensitivity, thus
reducing blood glucose level. The reduction of hepatic
gluconeogenesis might be at least partly involved in the
mechanism.
Steatosis may partly play a causal role in obesity-
induced insulin resistance. We investigated the effect of
SOD1 expression on hepatic lipid accumulation by Oil Red
O staining. The overexpression of SOD1 increased lipid
accumulation in liver of db/db mice (data not shown).
Thus, the improvement of insulin sensitivity in this model
is independent of the change of steatosis.
SOD1 expression in liver reduces PGC-1 expres-
sion. To investigate the mechanism of improvement of
hepatic insulin sensitivity by overexpression of SOD1, we
measured the mRNA expression of the main regulators of
glucose metabolism in the liver by quantitative real-time
PCR. Overexpression of SOD1 signiﬁcantly reduced the
expression levels of PEPCK, the rate-limiting enzyme of
gluconeogenesis. It also modestly reduced the expression
level of G6Pase, although the effect was not statistically
signiﬁcant. These changes in the expression of gluconeo-
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FIG. 3. Gene expression levels of key metabolic regulators and PGC-1
protein expression in liver overexpressing SOD1. At 7 days after
injection of AdLacZ or AdSOD1 into db/db mice, livers were collected
after overnight fasting. A: Total RNA was isolated from the liver of
each mouse at fasting state. The mRNA expression levels of key
metabolic regulators were measured by real-time RT-PCR. Data were
corrected by the expression level of TATA box–binding protein. The
relative expression level was calculated by setting the expression level
in the liver of mice injected with AdLacZ as 1. Values are means  SD
of 5–6 experiments. *P < 0.05 vs. AdLacZ group. B: The liver homog-
enates were immunoblotted with anti–PGC-1 antibody. The relative
expression level was calculated by setting the expression level in the
liver of db/m mice as 1. Values are means  SD of 4 experiments. *P <
0.05 vs. db/dband AdLacZ groups.
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mRNA and protein-level PGC-1, which is the main regu-
lator of the expression of both gluconeogenic genes
(16,17). On the other hand, overexpression of SOD1 did
not alter the gene expression of glucokinase, the rate-
limiting enzyme of glycolysis (Fig. 3). These data indicate
that downregulation of PGC-1, which is a main regulator
of gluconeogenic genes, may play a key role in the
improvement of glucose tolerance by the reduction of ROS
in db/db mice.
Overexpression of SOD1 increased the phosphoryla-
tion of Foxo1 independently of Akt phosphorylation
level in the liver. Insulin suppresses the expression of
the PGC-1 gene at least partly through Akt-stimulated
phosphorylation of forkhead box class O1 (Foxo1) (18).
Thus, we investigated the insulin-signaling transduction
pathway in liver of AdLacZ- and AdSOD1-treated db/db
mice. Although IRS-1 and IRS-2 are both important mole-
cules involved in insulin signaling, the expression of IRS-1
protein in AdSOD1 group was signiﬁcantly higher, and the
expression of IRS-2 protein signiﬁcantly lower, than that in
the AdLacZ group (Fig. 4A). We quantitatively conﬁrmed
the changes of the expression of these proteins (data not
shown). Parallel to the respective expression level, insulin-
stimulated tyrosine phosphorylation of IRS-1 was higher
and that of IRS-2 was lower in AdSOD1-treated mice than
in AdLacZ-treated mice (Fig. 4A). Reﬂecting these
changes, the binding afﬁnity to p85, a subunit of PI3 kinase
of IRS-1, was higher and that of IRS-2 was lower in
AdSOD1-treated mice than in AdLacZ-treated mice (Fig.
4A). Probably because the reduced IRS-2 phosphorylation
cancounteracttheincreasedIRS-1phosphorylation,insulin-
stimulated phosphorylation of Akt might not be eventually
affected by overexpression of SOD1 (Fig. 4A). IRS-1 is
phosphorylated at Ser
307 residue (5,19,20) by several cyto-
kines; this modiﬁcation reduces insulin-stimulated ty-
rosine phosphorylation of IRS-1 and stimulates the
degradation of IRS-1 (21,22). Thus, we investigated the
effect of reduction of ROS on the phosphorylation of IRS-1
at the Ser
307 residue. As shown in Fig. 4B, phosphorylation
of IRS-1 at the Ser
307 residue was reduced by reduction of
ROS. These ﬁndings indicate that the increase of insulin-
stimulated tyrosine phosphorylation of IRS-1 by the reduc-
tion of ROS in liver of db/db mice is associated with the
decreased phosphorylation of IRS-1 at the Ser
307 residue.
Finally, we examined the phosphorylation of Foxo1 at
Ser
256. Although no signiﬁcant change in the phosphoryla-
tion level of Akt was observed in association with SOD1
overexpression, the phosphorylation of Foxo1 was signif-
icantly augumented by the SOD1 overexpression (Fig. 4C).
This ﬁnding suggests that the phosphorylation of Foxo1 at
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FIG. 4. Insulin induces phosphorylation and expression of Akt, IRS-1,
IRS-2, and Foxo1 in the liver. A: At 7 days after treatment of db/db mice
with AdLacZ or AdSOD1, livers were collected at 5 min after injection
of 0.5 units of regular insulin through the inferior vena cava or without
the injection of insulin. Whole cell extracts were applied for immuno-
precipitation assay using anti–IRS-1 or anti–IRS-2 antibody. The im-
munoprecipitated samples were applied for Western blotting analysis
using the indicated antibodies. Representative results of 3–4 experi-
ments are shown. The lower panel showed Akt phosphorylation level in
each group. Whole cell extracts from the livers were applied for the
detection of insulin-induced Akt phosphorylation (AdLacZ insulin [],
n  4; AdLacZ insulin [], n  7; AdSOD1 insulin [], n  5; AdSOD1
insulin [], n  7). B: Liver homogenates were immunoblotted with
anti–phosphoIRS-1(Ser
307) antibody or anti–IRS-1 antibody (n  7 for
each treatment). The relative Ser
307 phosphorylated IRS-1 expression
level was expressed by setting the mean density of blots of AdLacZ as
1. C: At 7 days after treatment of db/db mice with AdLacZ or AdSOD1,
livers were collected at 5 min after injection of 0.5 units of regular
insulin through the inferior vena cava or without the injection of
insulin. Whole cell extracts were applied for immunoprecipitation
assay using anti-Foxo1 antibody. The immunoprecipitated samples
were applied for Western blotting analysis using anti–phospho-FKHR
(Ser
256) antibody. Representative results of 5–6 experiments are
shown. Values are means  SD. ¶P < 0.05 vs. AdLacZ insulin [] group;
$P < 0.05 vs. AdSOD1 insulin [] group; *P < 0.05 vs. corresponding
AdLacZ groups.
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256 may be regulated by oxidative stress, independent
of Akt activity.
Overexpression of SOD1 reduces phosphorylation of
CREB. In response to glucagon, protein kinase A phos-
phorylates transcription factor CREB at Ser
133 and in-
creases its transcriptional activity (23), which activates
the expression of PGC-1 and gluconeogenic genes
(16,17). Overexpression of SOD1 reduced phosphorylation
of CREB (Fig. 5). This result indicates that the reduced
expression of PGC-1 associated with reduction of ROS in
liver is accompanied by reduced phosphorylation of
CREB.
ROS induces phosphorylation of CREB and PGC-1
gene expression in hepatocytes. Next, to investigate
whether ROS induces the phosphorylation of CREB and,
hence, results in activation of PGC1 in hepatocytes, we
loaded ROS to a hepatocyte-derived cell line, Huh7 cells,
by the addition of xanthine and xanthine oxidase, which
generate superoxides. The combination of both com-
pounds augmented CREB phosphorylation, but their effect
was suppressed by BHA (a scavenger of free radicals) and
MnTBAP (an SOD mimetic material) (Fig. 6A). Reﬂecting
the changes in phosphorylation of CREB, ROS augmented
PGC-1 expression, and this effect was blocked by pre-
treatment with BHA or MnTBAP (Fig. 6B). These results
indicate that high ROS levels activate CREB phosphoryla-
tion and result in increased expression of PGC-1.
Previous studies showed that ROS induced phosphory-
lation and activation of mitogen-activated protein kinases
(MAPKs) (5,24–26). In addition, ERK and p38 MAPK
regulate the phosphorylation of CREB in hepatocytes and
liver (27–29). Thus, we investigated the causal relationship
between activation of MAPK and phosphorylation of
CREB in the pathogenesis of liver insulin resistance. As
shown in Fig. 6C, phosphorylation of CREB was higher in
db/db mice than in db/m mice. The increased phosphory-
lation of CREB was restored by AdSOD1. We measured
the phosphorylation state of each MAPK in the same
samples. Among MAPKs, only the phosphorylation level of
JNK tended to be similar to that of CREB. Next, we
investigated the causal relationship between phosphoryla-
tion of JNK and CREB in Huh7 cells. As shown in Fig. 6D,
ROS induced JNK phosphorylation, which was in turn
counteracted by the addition of antioxidants. ROS-induced
phosphorylation of CREB was also blocked by the addi-
tion of JNK-speciﬁc inhibitor SP600125 (Fig. 6E). In addi-
tion, ROS-induced activation of PGC-1 was counteracted
by SP600125 (Fig. 6F). These results indicate that ROS-
induced JNK activation is at least in part involved in the
pathogenesis of hepatic insulin resistance, through the
activation of CREB.
DISCUSSION
In this study, we investigated the role of ROS on hepatic
glucose metabolism in type 2 diabetes. The major ﬁndings
of the present study were that the ROS–JNK–CREB–
PGC-1 pathway is at least in part involved in the patho-
genesis of liver insulin resistance.
Hyperglycemia observed in the diabetic state largely
depends on increased hepatic glucose production and
reduced glucose uptake in peripheral tissues. In particular,
increased hepatic gluconeogenesis plays an important role
in the pathophysiology of hyperglycemia (30). The regula-
tion of gluconeogenesis predominantly depends on the
expression level of gluconeogenic genes such as PEPCK
and G6Pase (31,32). In the present study, overexpression
of SOD1 suppressed the expression of gluconeogenic
genes. The pyruvate challenge test showed that SOD1
expression in db/db mice reduced gluconeogenesis. Thus,
whereas we cannot exclude the possibility that the reduc-
tion of ROS in liver altered peripheral insulin sensitivity, it
is likely that the improvement in glucose level following
reduction of ROS in the liver is mainly caused by reduced
expression of gluconeogenic genes.
The body weight of AdSOD1-treated mice was higher
than that of AdLacZ-treated and PBS-injected mice (Fig.
2B), although food intake of AdSOD1-treated mice was
comparable with that of AdLacZ-treated and PBS-injected
mice (data not shown). Accordingly, the increase in body
weight was not due to the increase in appetite associated
with the treatment of AdSOD1. In AdSOD1 mice, insulin
sensitivity was improved and blood glucose was efﬁciently
reduced. Accordingly, the body-weight gain in AdSOD1-
treated mice might be due to the decrease of the urinary
glucose excretion and the increase of glucose absorption
in insulin-sensitive tissue.
PGC-1 functions as a coactivator of several transcrip-
tion factors that play critical roles in hepatic glucose
metabolism by regulating the expression of gluconeogenic
genes (16,17). The expression of PGC-1 is markedly
increased in the liver of diabetic rodents (16,17), and
inhibition of hepatic PGC-1 expression results in almost
complete normalization of fasting glucose level and glu-
cose tolerance in db/db mice (33). Furthermore, in nondi-
abetic rodents, inhibition of PGC-1 reduces hepatic
glucose output along with downregulation of PEPCK and
G6Pase expression (33). In the present study, PGC-1
expression was markedly suppressed by SOD1 overex-
pression, and this seemed to be a key molecular mecha-
nism in the inhibition of gluconeogenesis.
Several studies reported that insulin reduces the expres-
sion of PGC-1 in the liver via the inactivation of Foxo1
(18,34–36). Therefore, amelioration of glucose tolerance
by reduction of ROS in the liver in db/db mice might
possibly be due to an increase in insulin signaling. How-
ever, the phosphorylation level of Akt, a key signal mole-
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FIG. 5. Effects of SOD1 overexpression on CREB phosphorylation. A:
At 7 days after treatment of db/db mice with AdLacZ or AdSOD1, livers
were collected after overnight fasting. The liver homogenates were
immunoblotted with anti–phospho-CREB (p-CREB) or anti-CREB an-
tibody (n  8 for each treatment). The relative expression level was
calculated by setting the expression level in the liver of mice injected
with AdLacZ as 1. Values are means  SD. *P < 0.05 vs. AdLacZ group.
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altered by reduction of ROS.
Whereas previous studies showed that Akt reduced
transactivation of Foxo1 through the phosphorylation of
Foxo1 at Ser
256 (37,38), our data demonstrated that the
phosphorylation of Foxo1 at Ser
256 was augmented by
reduction of ROS independently of the insulin signal at Akt
phosphorylation level. Very recently, it was reported that
the phosphorylation of Foxo1 is regulated by phospha-
tases such as protein phosphatase 2A and Ca
2	-dependent
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FIG. 6. ROS induces CREB phosphorylation
and PGC-1 gene expression in Huh7 cells.
A: After overnight starvation, Huh7 cells
were treated with 400 mol/l xanthine
(XA) and 40 mU/ml xanthine oxidase (XO).
The cell extracts were then applied for
Western blotting to detect CREB phosphor-
ylation. When antioxidants were used, 400
mol/l BHA or 400 mol/l MnTBAP was
added to the medium 20 min before treat-
ment with XA and XO. Representative re-
sults of 4 experiments were shown. B: After
overnight starvation, Huh7 cells were
treated with 400 mol/l XA and 40 mU/ml
XO for 180 min. Total RNA extracted from
each cell was then applied for real-time
RT-PCR to quantitate the expression of
PGC-1. Values are means  SD of 4–5
experiments. #P < 0.05 vs. pretreatment
() before XA and XO treatment. ‡P < 0.05
vs. pretreatment () after XA and XO
treatment. C: Seven days after intravenous
injection of PBS into db/m mice or of PBS,
AdLacZ, or AdSOD1 into db/db mice, liver
was harvested and applied for immunoblot-
ting with the corresponding antibody. Data
represent the amounts of phosphorylated
protein divided by the amount of the re-
spective protein. The relative expression
level was calculated by setting the expres-
sion level in liver of db/m mice as 1. Values
are means  SD. *P < 0.05 vs. db/db and
AdLacZ groups. D: After overnight starva-
tion, Huh7 cells were treated with 400
mol/l XA and 40 mU/ml XO. The phosphor-
ylation of JNK was assessed at 15 and 60
min after treatment. The antioxidant (BHA
400 mol/l or MnTBAP 400 mol/l) was
added at 20 min before the addition of XA
and XO. Representative results of four ex-
periments were shown. E: Thirty micromo-
lars of SP600125, a JNK-speciﬁc inhibitor,
were pretreated instead of antioxidants.
The phosphorylation of CREB and JNK
were then assessed at 15 and 60 min after
treatment. Representative results of 4 ex-
periments were shown. F: After overnight
starvation, Huh7 cells were treated with
400 mol/l XA and 40 mU/ml XO. Total RNA
extracted from each cell was then applied
for real-time RT-PCR to quantitate the ex-
pression of PGC-1. Thirty mol/l SP600125
were added 20 min before the addition of XA
and XO. Values are means  SD of 4–5 ex-
periments. #P < 0.05 vs. pretreatment ()
before XA and XO treatment. ‡P < 0.05 vs.
pretreatment () after XA and XO treat-
ment for 180 min.
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phosphatase 2A and calcinurin are known to be activated
by ROS (41–46). Therefore, the overexpression of SOD1
may augment the phosphphorylation of Foxo1 by the
reduction of phosphatase activity.
While Foxo1 is known as a positive regulator of PGC-
1, CREB, which is activated by glucagon and epineph-
rine, is the main regulator of the PGC-1 expression in the
liver (16,17). In the present study, we demonstrated that
downregulation of PGC-1 expression, elicited by reduced
ROS levels in the liver, is accompanied by decreased
phosphorylation of CREB in db/db mice. These results
demonstrate the association of tissue ROS level and phos-
phorylation level of CREB. A previous study indicated that
the expression level of PGC-1 is increased by hydrogen
peroxide in mouse ﬁbroblasts and that such an increase
was mediated by CREB phosphorylation (47). In the
present study, we found that ROS induced phosphoryla-
tion of CREB and activation of PGC-1 gene expression in
Huh7 cells. Thus, ROS-induced CREB phosphorylation
may be a common signal pathway in different kinds of
cells. Reduction of ROS in liver is a potentially effective
strategy to improve insulin resistance.
Previous studies showed that ROS phosphorylates and
activates MAPKs in both hepatocytes and liver (5,24–26)
and that ERK and p38 MAPK activate CREB. We found
that only the phosphorylation of JNK is associated with
ROS level in liver among MAPKs. Furthermore, in Huh7
cells, activation of CREB by ROS was suppressed by the
JNK inhibitor. Although the mechanism of JNK-mediated
CREB phosphorylation should be elucidated, JNK at least
partly mediates ROS-induced hepatic insulin resistance
through the activation of CREB.
With regard to the effect of ROS on insulin signaling, we
investigated tyrosine phosphorylation of IRS-1 and IRS-2.
Interestingly, reduction of ROS increased tyrosine phos-
phorylation of IRS-1 but decreased tyrosine phosphoryla-
tion of IRS-2. With regard to the changes in expression and
tyrosine phosphorylation of IRS-1, reduction of ROS atten-
uated phosphorylation of IRS-1 at the Ser
307 residue. In the
present study, reduction of ROS also attenuated JNK
activation. JNK reportedly phosphorylates IRS-1 at the
Ser
307 residue (5,19,20) and stimulates the degradation of
IRS-1 (21,22). Thus, it is likely that reduction of ROS
increases the phosphorylation and expression of IRS-1
through a reduction of JNK activity. With regard to IRS-2,
the gene expression is positively regulated by CREB in the
liver (48). Thus, reduction of ROS in liver might reduce the
gene expression of IRS-2 by attenuating CREB phosphor-
ylation. Probably because of the opposite changes of
insulin signal at IRS-1 and IRS-2, Akt phosphorylation was
not affected by reduction of ROS.
In the present study, we used overexpression of SOD1
as a strategy to reduce ROS levels in the liver. As a result
of the mitochondrial and cytosolic location of SOD1 in
liver (7), overexpression of SOD1 theoretically reduces
both mitochondria and cytosolic superoxide. Recently,
Imoto et al. (5) reported that ROS derived from mitochon-
dria attenuate insulin signaling in cultured hepatocytes. To
determine whether the effect of SOD1 on hepatic insulin
resistance is different from that of SOD2 (mitochondrial
isoform), we investigated the effect of overexpression of
SOD2 in the liver of db/db mice using the same strategy as
was used for SOD1 treatment in the present study. We
found that treatment of db/db mice with AdSOD2 reduced
blood glucose level and ameliorated glucose tolerance and
that the effect was almost similar to overexpression of
AdSOD1 (N. Kumashiro and H. Watada, unpublished ob-
servations). These results suggest that the reduction of
ROS derived from mitochondria may play a key role in the
improvement of insulin sensitivity.
In conclusion, our data show that the decreased PGC-1
expression is at least in part involved in the amelioration
of liver insulin resistance by the reduction of ROS. The
present results suggest that this signal pathway is a
potentially suitable therapeutic target for the treatment of
type 2 diabetes.
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